SHR-1701 plus Bevacizumab and Chemotherapy in EGFR-mutated NSCLC

Phase 3, randomised, double-blind trial of retlirafusp alfa in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (3 arms), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Incidence and severity of adverse events, serious adverse events, and immune-related adverse events at 2 years and BIRC-assessed Progression-Free Survival at 2 years. Status: unknown.